Study #2017-0725
Cabosun Ii: Cabozantinib versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma
MD Anderson Study Status
Not Accepting
Treatment Agent
Cabozantinib, Sunitinib Malate
Description
The goal of this clinical research study is to compare the safety and effectiveness of cabozantinib and sunitinib when given to patients with metastatic (has spread) variant histology renal cell carcinoma (vhRCC), a type of kidney cancer. This is an investigational study. Cabozantinib and sunitinib are both FDA approved and commercially available for the treatment of advanced kidney cancer, including vhRCC. The study doctor can explain how the study drugs are designed to work. Up to 84 participants will be enrolled in this study. All will take part at MD Anderson.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
Study phase:
Phase II
Physician name:
Matthew Campbell
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-844-982-1565
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.